• Polomar Health Services filed a Form 12b-25 to delay its quarterly report on Form 10-Q for the period ended March 31, 2026, citing an inability to compile all required financial statement information without unreasonable effort or expense.
• Revenue rose to about 1.01 million for the quarter from 4,542 a year earlier, driven by a shift from a retail to a wholesale model with higher fulfillment of sterile compounded drug prescriptions.
• Operating expenses increased to about 575,850 from about 398,836, led by shipping, payroll, and legal and accounting costs tied to SEC filings and a planned merger with Altanine.
• Net loss narrowed to about 25,379 from about 415,408.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polomar Health Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-024128), on May 18, 2026, and is solely responsible for the information contained therein.